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Abstract
Background: It is commonly recommended that microbiological assessment should accompany the use of
antibiotics prone to resistance. We sought to estimate the rate of microbiology testing and compare this to
dispensing of the World Health Organization classified “watch” group antibiotics in primary care.
Methods: Data from a cohort of older adults (mean age 69 years) were linked to Australian national health
insurance (Pharmaceutical Benefits Scheme & Medicare Benefits Schedule) records of community-based antibiotic
dispensing and microbiology testing in 2015. Participant characteristics associated with greater watch group
antibiotic dispensing and microbiology testing were estimated using adjusted incidence rate ratios (aIRR) and 95%
confidence intervals (CI) in multivariable zero-inflated negative binomial regression models.
Results: In 2015, among 244,299 participants, there were 63,306 watch group antibiotic prescriptions dispensed
and 149,182 microbiology tests conducted; the incidence rate was 0.26 per person-year for watch group antibiotic
dispensing and 0.62 for microbiology testing. Of those antibiotic prescriptions, only 19% were accompanied by
microbiology testing within − 14 to + 7 days. After adjusting for socio-demographic factors and co-morbidities,
individuals with chronic respiratory diseases were more likely to receive watch group antibiotics than those without,
e.g. asthma (aIRR:1.59, 95%CI:1.52–1.66) and chronic obstructive pulmonary disease (COPD) (aIRR:2.71, 95%CI:2.48–
2.95). However, the rate of microbiology testing was not comparably higher among them (with asthma aIRR:1.03,
95%CI:1.00–1.05; with COPD aIRR:1.00, 95%CI:0.94–1.06).
Conclusions: Priority antibiotics with high resistance risk are commonly dispensed among community-dwelling
older adults. The discord between the rate of microbiology testing and antibiotic dispensing in adults with chronic
respiratory diseases suggests the potential for excessive empirical prescribing.
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Background
Antibiotic resistance is a severe threat to global public
health. It is estimated that each year infections caused
by antibiotic-resistant pathogens result in 700,000 deaths
worldwide; the number might reach 10 million in 2050
if there is no effective action to curb resistance [1]. The
overuse of antibiotics is considered as an important con-
tributor to antibiotic resistance, [2] which could be ef-
fectively reduced by appropriate antibiotic stewardship
[3]. To guide the use of antibiotics, the World Health
Organization (WHO) proposed a three-category anti-
biotic classification system in 2017 [4]: namely access,
watch, and reserve group antibiotics. Access group anti-
biotics are the first-line choices for common infections;
watch group antibiotics are those with greater potential
for developing resistance; and reserve group antibiotics
are those considered “last resort” antibiotics for infec-
tions. WHO recommends that antibiotics in the watch
and reserve groups (see Supplementary Table 1) should
be limited to particular conditions and need special
stewardship and monitoring [4]. There are also restricted
antibiotic lists proposed in several countries for limiting
the use of those antibiotics with high resistance potential
[5–7]. Clinical guidelines for antibiotic prescribing in
these countries also do not recommend them as the first
choice for empirical therapy for common conditions in
the community, e.g. respiratory tract infections, skin/
wound infections, and urinary tract infections [8–10].
Earlier epidemiological studies and surveillance pro-
grams, nationwide and worldwide, have reported the use
of some classes of watch/reserve group antibiotics and
their relationship with antibiotic resistance in the popula-
tion, e.g. the use of macrolides and Streptococcus pneumo-
niae resistance [11, 12], and the use of fluoroquinolones
and cephalosporins and Escherichia coli resistance [11–
13]. Some emerging multidrug-resistant organisms, in-
cluding methicillin-resistant Staphylococcus aureus
(MRSA) and vancomycin-resistant Enterococcus (VRE),
were also reported to be associated with the use of quino-
lines and extended-spectrum cephalosporins [14, 15].
However, there are limited data describing the use of
watch/reserve group antibiotics among different popula-
tion subgroups, especially susceptible elderly people with
major chronic diseases or living in Long-Term Care Facil-
ities (LTCF), and comparing the rate of antibiotic dispens-
ing with microbiology testing in primary care settings.
Therefore, we examined the incidence rate of watch/re-
serve group antibiotic dispensing among community-
dwelling older adults and compared it with the rate of
microbiology testing for bacterial infections according to
individual chronic health conditions in a large Australian
cohort, in order to better understand the pattern of
watch/reserve group antibiotic dispensing in general
practice.
Methods
Study population and data sources
We used the Sax Institute’s 45 and Up Study, a large-
scale cohort which recruited 267,153 participants aged
≥45 years from 2006 to 2009 in the largest Australian
state, New South Wales (NSW). Participants were
randomly sampled from the Department of Human
Services (DHS) enrolment database. Detailed informa-
tion on the cohort has been published previously [16].
Approximately 10% of adults aged 45 years and over in
the general population of NSW were recruited. Partici-
pants completed a questionnaire at baseline about their
demographics, lifestyle, and health information (avail-
able at https://www.saxinstitute.org.au/our-work/45-
up-study/questionnaires/). They also agreed to have
their questionnaire information linked to their health
records. In this study, we linked the cohort to the
Pharmaceutical Benefits Scheme (PBS), Medicare Bene-
fits Schedule (MBS) based on a unique identifier pro-
vided by the DHS, and the NSW Admitted Patient Data
Collection (APDC), and the NSW Registry of Births,
Deaths and Marriages (RBDM) database through prob-
abilistic linkage by the NSW Centre for Health Record
Linkage (CHeReL).
The PBS database records medicines dispensed for
outpatients subsidized by the Australian government
pharmaceutical scheme; data include the dates of dis-
pensing, medicine names, and WHO Anatomical Thera-
peutic Chemical (ATC) codes. About 98% of recorded
antibiotic prescriptions in the PBS database were sup-
plied from community pharmacies; others were supplied
from private hospitals or other healthcare facilities [17].
The MBS database records general practitioner (GP)
visits and other medical services provided to patients
subsidized by the Australian government. The data in-
clude the types of service, the dates of service conducted,
and the codes for service item (MBS item number). The
APDC database records patient hospital admissions in
NSW; data include the admission dates and diagnoses
coded according to the International Classification of
Diseases version 10 Australian Modification (ICD-10-
AM). The RBDM database records registered death in-
formation, including the death dates of participants.
Ethics
The study was approved by the University of New South
Wales Human Research Ethics Committee (number
10186), and the NSW Population and Health Services
Research Ethics Committee (HREC/10/CIPHS/97).
Outcomes
Our primary outcome was the number of watch and re-
serve group systemic antibiotic prescriptions dispensed
to each cohort participant recorded in the PBS database
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from 1st January 2015 to 31st December 2015 (observa-
tion period). The list of antibiotics classified as watch/re-
serve group is shown in Supplementary Table 1. We
identified the antibiotic classes by their ATC codes [18].
A secondary outcome was the number of microbiology
tests for bacterial infections received by each participant
during 2015 based on records in the MBS database (see
Supplementary Table 2). Some serology tests which
might be used for diagnosing bacterial infections were
also included. We excluded those microbiology tests
only for viral, parasitic or fungal pathogens, and those
tests provided in hospitals. As another secondary out-
come, we examined the number of prescriptions of
amoxicillin-clavulanate (ATC code J01CR02), the main
broad-spectrum beta-lactam antibiotic outside the
watch/reserve group dispensed in Australia during 2015
from the PBS database, since for many conditions pre-
scriptions of this antibiotic would also require accom-
panying microbiology testing [10].
Covariates
Socio-demographic factors for each participant were de-
rived from the 45 and Up Study baseline questionnaire.
We included sex (men or women), age-group in 2015
(45–59, 60–64, 65–69, 70–74, 75–79, and ≥ 80 years),
education (university degree or higher, certificate or vo-
cational education, no school certificate), annual house-
hold income at baseline in Australian dollars (low: <$30,
000, middle: $30000- < $70,000, high: ≥$70,000), and
residential area (major city, regional/remote area). Miss-
ing values in each covariate were included as a separate
group.
The primary patient subgroups of interest in our study
were those with major chronic diseases and those living
in LTCF. We derived co-morbidities and other health
service use from the MBS and APDC databases. For par-
ticipants who were dispensed watch/reserve group anti-
biotics during 2015, an index date was defined as the
first date of watch/reserve group antibiotic dispensing;
for participants who were not provided watch/reserve
group antibiotics, the index date would be 9th July 2015,
the median date of watch/reserve group antibiotic dis-
pensing among participants. Residence in a LTCF was
ascertained if participants had an MBS record of a med-
ical service in a LTCF (see Supplementary Table 2 for
codes) in the year before the index date. A history of
major chronic diseases was based on hospitalization re-
cords within 3 years before the index date in the NSW
APDC database, defined by the primary diagnosis codes
(ICD-10-AM): cancer (C00-C97), diabetes mellitus (E10-
E14), chronic obstructive pulmonary disease (COPD,
J40-J44), chronic kidney disease (N18), and cardiovascu-
lar diseases (i.e. ischemic heart diseases or stroke, I20-
I25 or I60-I69). We also included self-reported asthma
that was indicated in the baseline questionnaire. The
number of GP consultations in the MBS database (see
Supplementary Table 2 for codes) and the number of
hospital admissions in the NSW APDC database in the
year before the index date were included as covariates
for each participant, as these factors were shown to be
associated with antibiotic use in a previous study [19].
Data analysis
In this analysis, we included participants who were alive
on 1January 2015 based on death records in the NSW
RBDM. Person-time in the analysis was calculated from
1 January 2015 to 31 December 2015 or date of death
whichever came first. We calculated the number and
incidence rate of watch/reserve group antibiotic
prescriptions dispensing, microbiology testing, and
amoxicillin-clavulanate dispensing in 2015 among the
study population overall and according to different indi-
vidual characteristics. Using multivariable zero-inflated
negative binomial regression, we estimated adjusted inci-
dence rate ratios (aIRR) and calculated 95% confidence
intervals (CI) to identify the associations of major co-
morbidity and residence in LTCF with watch/reserve
group antibiotic dispensing and microbiology testing.
We also assessed risk factors for the dispensing of
macrolides (in the WHO watch group but not in the
Australian restricted antibiotics list [7]), other watch/re-
serve group antibiotics, and amoxicillin-clavulanate sep-
arately. To verify the potential effect of prior antibiotic
use on watch/reserve group antibiotic dispensing, we
performed a sensitivity analysis and only included those
watch/reserve group antibiotics without antibiotic
prescriptions in the 14 days prior. All the socio-
demographic, co-morbidities, and health service-related
covariates described above were included in the model.
We also examined the timing of microbiology tests in
relation to the dispensing of watch/reserve group antibi-
otics. We calculated the proportion of watch/reserve
group antibiotic prescriptions that had an accompanying
microbiology test performed within 14 days prior to or
7 days after the dispensing date for study populations,
considering that the tests performed around the day of
dispensing are potentially related to the antibiotic
treatment.
All analyses were conducted using Stata version 14.1.
Two-sided P value< 0.05 was used as the threshold for
statistical significance.
Results
After excluding people who died before 2015, we in-
cluded 244,299 individuals (mean age 69 years) of whom
120,747 (49%) were dispensed ≥1 antibiotic prescription
in 2015. Among those 120,747 participants, a total of
403,492 antibiotic prescriptions were dispensed, of
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which 63,306 (16%) were watch/reserve group antibi-
otics. There were 29,917 (12%) participants who were
dispensed at least one watch/reserve group antibiotic
prescription: 13,914 (5.7%) were dispensed one; 10,102
(4.1%) were dispensed two; and 5901 (2.4%) were dis-
pensed three or more prescriptions. There were fewer
than five reserve group antibiotic prescriptions; thus,
they were included in the watch group analyses; and in
the following text, we simply refer to the group as watch
group. As shown in Table 1, the most commonly dis-
pensed watch group antibiotics were macrolides (53,336
prescriptions), followed by quinolones and fluoroquino-
lones (8519 prescriptions). Among non-watch group an-
tibiotics, amoxicillin-clavulanate was dispensed in 67,735
(17%) prescriptions. Over the observation period, there
were 149,182 microbiology tests for bacterial infections
conducted in the study population. The distribution of
the intervals between a dispensed watch group antibiotic
prescription and its closest microbiology test is shown in
Supplementary Figure 1, 69% of which were in the − 14
days to + 7 days window.
In 2015, the incidence rate was 0.26 per person-year
for watch group antibiotic dispensing and 0.62 per
person-year for microbiology testing (Table 2). Overall,
11,993 (19%) watch group antibiotic prescriptions had a
microbiology test within − 14/+ 7 days and were
regarded as watch group prescriptions with a related
microbiology test. Most patients with major chronic dis-
eases or living in a LTCF had a higher incidence rate of
watch group antibiotic dispensing, microbiology testing,
and a higher proportion of antibiotic prescriptions with
a related test when compared with other populations.
However, patients with chronic respiratory diseases, i.e.
COPD and asthma, were the exceptions, as only 17% of
their prescriptions had a related microbiology test, lower
than the rest of study populations.
After adjustment in multivariable analysis (Fig. 1 and
Supplementary Table 3), cancer, diabetes, and chronic
kidney diseases were not associated with watch group
antibiotic dispensing but associated with a higher likeli-
hood of microbiology testing. Cardiovascular diseases
were not associated with watch group antibiotic dispens-
ing nor microbiology testing. The pattern of antibiotic
dispensing and microbiology testing in COPD and
asthma patients was different from patients with other
chronic diseases. While both were strongly associated
with greater use of watch group antibiotics, (COPD IRR:
2.71, 95%CI: 2.48–2.95, asthma IRR:1.59, 95%CI: 1.52–
1.66), there was almost no increase in microbiology test-
ing in COPD (aIRR:1.00, 95%CI: 0.94–1.06) and asthma
(aIRR:1.03, 95%CI: 1.00–1.05) patients, if compared with
people without COPD (asthma). Besides, in comparison
with people not living in LTCF, those living in LTCF
had a lower likelihood of receiving watch group pre-
scriptions (aIRR: 0.91. 95%CI: 0.85–0.99) but a higher
likelihood of microbiology testing (aIRR: 1.31 95%CI:
1.26–1.37).
Supplementary Table 4 shows that the incidence rate
was 0.28 per person-year for amoxicillin-clavulanate dis-
pensing. After adjustment, COPD, asthma, cancer, dia-
betes, and chronic kidney diseases, were all significantly
associated with a higher likelihood of amoxicillin-
clavulanate dispensing. When we restricted watch group
antibiotic prescriptions to those without antibiotic pre-
scriptions in the 14 days prior, we found that 39,088
(62%) prescriptions did not follow prior antibiotic use,
and the association of chronic respiratory diseases with
watch group antibiotic dispensing did not substantially
change (see Supplementary Table 5). The incidence rate
ratios for certain classes of watch group antibiotic dis-
pensing and microbiology testing by type of test are
shown in Supplementary Table 6 and 7, respectively.
Given the strong association of chronic respiratory dis-
eases with watch group antibiotic dispensing, we further
examined the relationships according to disease severity
(Supplementary Table 8). We divided the population
into four groups: 1) no asthma or COPD history; 2) only
asthma; 3) less severe COPD (COPD hospitalization < 2
times in the past 3 years); and 4) more severe COPD
(COPD hospitalization ≥2 times in the past 3 years). The
Table 1 Number of dispensed antibiotic prescriptions and




Watch and reserve group a, b 63,306 (16)
Macrolides (ATC code: J01FA) 53,336 (13)
Quinolones and fluoroquinolones (ATC code: J01M) 8519 (2.1)
Others c 1451 (0.36)
Antibiotics not in watch or reserve group 340,186 (84)
Amoxicillin-clavulanate (ATC code: J01CR02) 67,735 (17)
Others 272,451 (68)
Microbiology test No. (%)
Total 149,182 (100)
By type
Urine examinations d 82,291 (55)
Microscopy & culture for specimens of sputum 4887 (3.3)
Microscopy & culture for other specimens 34,014 (23)
Microbial antigens, nucleic acid, or antibody testing 24,432 (16)
Others 3558 (2.4)
a. As defined by the WHO Model List of Essential Medicines in 2017
b. Included reserve group antibiotics (N < 5)
c. Included 3rd&4th-generation cephalosporins (ATC code: J01DD, J01DE),
glycopeptides (ATC code: J01XA), ticarcillin and a beta-lactamase inhibitor
(ATC code: J01CR03)
d. Included microscopy and culture
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Table 2 Number and incidence of dispensed watch group antibiotic prescriptions and microbiology tests by participants’
characteristics
Characteristic Watch group antibiotic prescriptions Microbiology tests
No. (%) Person-years No. Incidence a No. (%) related to a test b No. Incidence
Total 244,299 (100) 242,195 63,306 0.26 11,993 (19) 149,182 0.62
Sex
Men 110,120 (45) 108,939 25,945 0.24 4908 (19) 58,787 0.54
Women 134,179 (55) 133,255 37,361 0.28 7085 (19) 90,395 0.68
Age (years)
45–59 54,148 (22) 54,079 9874 0.18 1648 (17) 23,162 0.43
60–64 44,072 (18) 43,987 9824 0.22 1643 (17) 21,594 0.49
65–69 41,952 (17) 41,825 10,274 0.25 1794 (18) 22,786 0.55
70–74 35,584 (15) 35,394 10,423 0.29 2015 (19) 23,529 0.67
75–79 26,644 (11) 26,431 8657 0.33 1809 (21) 20,834 0.79
≥ 80 41,889 (17) 40,478 14,254 0.35 3084 (22) 37,277 0.92
Education
University degree or higher 58,569 (24) 58,292 12,378 0.21 2395 (19) 31,232 0.54
Certificate or vocational education 155,309 (63) 153,930 40,426 0.26 7556 (19) 95,465 0.62
No certificate 26,824(11) 26,447 9424 0.36 1849 (20) 19,970 0.76
Missing 3597(1.5) 3527 1078 0.31 193 (18) 2515 0.71
Annual household Income c
High 61,321 (25) 61,174 11,917 0.20 2252 (19) 28,887 0.47
Middle 64,662 (27) 64,297 14,739 0.23 2801 (19) 35,768 0.56
Low 67,170 (28) 66,197 21,235 0.32 4183 (20) 49,568 0.75
Unknown 51,146 (21) 50,526 15,415 0.31 2757 (18) 34,959 0.69
Area of residence
Regional/remote area 113,290 (46) 112,373 25,942 0.23 5132 (20) 67,442 0.60
Major city 126,392 (52) 125,241 36,317 0.29 6679 (18) 79,168 0.63
Missing 4617 (1.9) 4581 1047 0.23 182 (17) 2572 0.56
History of chronic diseases
Asthma 30,608 (13) 30,333 14,635 0.48 2522 (17) 21,914 0.72
COPD 3540 (1.5) 3272 4702 1.44 810 (17) 4034 1.23
Cancer 16,355 (6.7) 15,583 5511 0.35 1265 (23) 14,942 0.96
Diabetes Mellitus 18,730 (7.7) 18,277 7719 0.42 1716 (22) 19,430 1.06
Choric Kidney Diseases 4532 (1.9) 4127 2381 0.58 632 (27) 7683 1.86
Cardiovascular diseases d 13,213 (5.4) 12,671 5537 0.44 1182 (21) 12,902 1.02
Residence in LTCF e
No 236,911 (97) 235,660 59,853 0.25 11,148 (19) 138,282 0.59
Yes 7388 (3.0) 6535 3453 0.53 845 (25) 10,900 1.68
a: per person-year
b: a watch/reserve prescription was defined as “related to a test” if there is microbiology testing within 14 days prior to or 7 days after the prescription
(see methods)
c: It is household income at baseline. Low: < 30,000 AUD, middle: 30000- < 70,000 AUD, high: ≥70,000 AUD
d: Included ischemic heart diseases and stroke
e: LTCF: Long Term Care Facilities
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test for linear trend showed a significant increase in the
likelihood of watch group antibiotic dispensing by dis-
ease severity (P < 0.001), but no increase in microbiology
testing (P = 0.161), which is consistent with the main
analysis.
Discussion
We found that in a large community-based cohort of
older people, there were 26 prescriptions of watch group
antibiotics dispensed and 62 microbiology tests for bac-
terial infections performed per 100 people in 2015. Only
19% of watch group antibiotic prescriptions were accom-
panied by microbiology testing within − 14 to + 7 days.
The patterns of antibiotic dispensing and microbiology
testing varied in patients with different chronic health
conditions after adjustment. Patients with cancer, dia-
betes, and chronic kidney diseases did not have a higher
likelihood of receiving watch group antibiotics but had a
higher likelihood of microbiology testing and receiving
amoxicillin-clavulanate. We found people with chronic
respiratory diseases, i.e. asthma and COPD, were signifi-
cantly more likely to receive watch group antibiotics as
well as amoxicillin-clavulanate; however, they did not
have a comparably higher likelihood of receiving micro-
biology testing. People in LTCF were not dispensed
more watch group antibiotics than those not in LTCF
but were more likely to be tested.
Although surveillance programs for antibiotic resist-
ance worldwide [20, 21] are constantly monitoring anti-
biotic consumption in the population, there are limited
data on the appropriateness of antibiotic use. Simply
looking at antibiotic consumption may not be enough
for fully understanding the factors driving antibiotic re-
sistance. The use of microbiology testing can be consid-
ered as a proxy for assessing the appropriateness of
antibiotic use [22]. But few studies have examined the
rate of microbiology testing in antibiotic treatment. It is
only known that empirical antibiotic treatment for infec-
tions is quite common in primary care: a study in Eur-
ope found that the proportion of empirical antibiotics
prescribed for urinary tract infection ranged from 59.4%
in the Netherlands to 95.1% in England [23].
When we compared the likelihood of watch group
antibiotic dispensing and microbiology testing in the
study population, there was a unique pattern identified
among people with asthma and COPD, i.e. the high like-
lihood of watch group antibiotics and amoxicillin-
clavulanate dispensing did not accompany a comparably
high likelihood of microbiology testing. Meanwhile,
these people had a lower proportion of antibiotic pre-
scriptions related to testing. Since the discord was not
observed in other patients with chronic diseases, we can-
not simply interpret it as the result of susceptibility to
infections or a higher likelihood of GP visits. A possible
explanation is that the discord might be the result of ex-
cessive watch group antibiotic use for exacerbation of
chronic respiratory diseases. On the one hand, routine
use of antibiotics for asthma exacerbation is not sup-
ported by sufficient evidence [24] but is common in clin-
ical practice according to studies in the US and Europe
[25–27]. On the other hand, although long-term macro-
lide use can effectively reduce the exacerbation of COPD
Fig. 1 Incidence rate ratio a for watch group antibiotic dispensing and microbiology testing by participants’ characteristics. a: Zero-inflated
negative binomial regression adjusted by sex, age, education level, income level, residential remoteness, residence in Long Term Care Facilities
(LTCF), history of chronic diseases, number of GP visits in the year before the index date, number of hospital admissions in the year before the
index date. b: aIRR: adjusted incidence rate ratio, CI: confidence intervals. c: Included ischemic heart diseases and stroke. d: LTCF: Long Term
Care Facilities
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due to its anti-inflammatory effect [28], it will signifi-
cantly increase the emergence of macrolide resistance
[29]. Currently, there is no agreement on the use of
long-term macrolides or clear suggestions about the
monitoring of antibiotic resistance in COPD guidelines
[10, 30, 31]. A previous study found that 38% of anti-
biotic use for COPD in hospitals might be inappropriate
[32], which was in line with our results in the commu-
nity setting. Taken together, our findings support more
comprehensive guidelines and stewardship among those
with chronic respiratory diseases, which requires identi-
fication of barriers to appropriate prescribing and poten-
tial mechanisms for monitoring of antibiotic use in these
populations. Future strategies may also include the es-
tablishment of clear and detailed criteria for selecting
patients who are suitable for macrolide prophylaxis in
COPD guidelines, [33] introduction of point-of-care
testing of C-reactive protein, which has been shown to
reduce antibiotic use among patients with COPD exacer-
bations by identifying those unlikely to benefit from
antibiotic therapy [34], and the use of novel macrolides
with anti-inflammatory effects but no antibiotic effects
which could reduce COPD exacerbations but not lead to
increases in antibiotic resistance [35].
Earlier studies reported that inappropriate antibiotic
prescribing was common among those living in LTCF
[36, 37]. Our study demonstrated that after adjusting for
age and comorbidities, the use of watch group antibi-
otics and amoxicillin-clavulanate was not significantly el-
evated in this group compared to those living outside of
LTCF; however, the likelihood of microbiology testing
was higher. The high likelihood of microbiology testing
may be the result of over-investigation for asymptomatic
bacteriuria, which frequently occurs in LTCF residents
[38].
A major strength of our study is the use of data link-
age of routinely collected administrative health data. To
our knowledge, this approach is underused in studies in-
vestigating antimicrobial stewardship. A limitation of
our study was the lack of clinical information to deter-
mine indications for antibiotic use and the results of
microbiology testing. Thus, we were unable to assess the
actual appropriateness of each prescription, and whether
its temporally related microbiology test was truly in the
same episode. Our comparison between rates of anti-
biotic dispensing and microbiology testing is a crude
measure of antibiotic stewardship and should be consid-
ered alongside other measures of appropriate antibiotic
prescribing. Besides, the MBS database only records the
three most expensive pathology items for one patient if
there are more than three tests during the one episode
(1 day) [39]. This issue will inevitably result in potential
under-ascertainment of testing in those episodes with
three or more testing records. We used a previously
published method [40] to estimate the scale of under-
ascertainment from potential incomplete records and
found that it would only affect about 11% of all episodes.
Therefore, this is unlikely to have a major impact on our
findings.
Conclusions
Watch group antibiotics are commonly dispensed
among older adults in the community. This is particu-
larly true for patients with asthma and COPD; however,
their likelihood of receiving microbiology testing is not
comparably high, indicating the potential for excessive
empirical watch group antibiotic use. Since watch group
antibiotics have high resistance potential, focusing anti-
biotic stewardship efforts might be needed among older
populations with chronic respiratory diseases in the pri-
mary care setting.
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